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We are writing in regard to the change in NICE guideline 1.4 published in April 2016 which
states that; patients over the age of 16 should not be routinely offered testing for sickle cell
disease or sickle cell trait before surgery. Rather, it advises that patients should be asked if
they or any member of the family have the disease.1 The guidance goes on to discuss the fact
that the number of operations completed by the National Health Service (NHS)  in the year
2012-2013 increased by 60% to 10.6 million, compared to those in 2002 – 2003, and
therefore ‘even a small percentage of unnecessary preoperative testing can affect a large
number of people’.
According to the summary of these guidelines, 2 they are based on General Dental Council
(GDG) consensus and the rational that; by adulthood sickle cell disease will be clinically
evident and whilst a test may discover an unknown trait, this would not alter the patient’s
management.
We would like to share our recent experience concerning a patient with a known sickle cell
trait undergoing orthognathic treatment at our unit.3 The operation planned was a Le Fort I
and posterior segment osteotomy. After an uneventful procedure and recovery period, the
patient returned for review at 2 weeks with obviously devascularised tissue bilaterally.
Despite antibiotics, hyperbaric oxygen treatment and therapeutic doses of Pentoxyfylline and
Vitamin E, these areas began to demarcate and teeth were lost bilaterally, whilst an oro-antral
fistula developed in the upper right quadrant.
Avascular necrosis of the maxilla after Le Fort I osteotomy is a rare complication that has
been reported to occur in <1% of cases. Blood flow to the maxilla is reduced by 50% in the
first post-operative day after sacrifice of the descending palatine arteries. However, there is
excellent collateral blood supply particularly if only one artery is sacrificed, as in this case.
Experimental studies have shown that loss of the descending palatine arteries results in a
transient ischaemic period that is compensated for by a vascular proliferation that allows
tissue healing. 4
As with many procedures, theoretically a period of hypoxia to the tissues would be expected
both during and after the procedure. This could in combination with other factors such as
hypotensive anaesthesia, hypothermia, acidosis and hypovolaemia could lead to the
conditions required to cause an ischaemic complication such as this.
We feel it is important that pre-operative surgical testing is considered on a case by case
basis, looking at both patient and operative factors. This may allow fully informed consent
and to possibly help both identify, or prevent post-operative ischaemic complications.
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